Table 3.

ASCs or CM treatment arrests the cardiac dysfunction in PF (Late phase)

	Con (n = 8)	B (n = 8)	B + M (n = 6)	BAD7 (n = 7)	BCM7 (n = 7)
RVSP	29.03 ± 1.25	45.71 ± 3.92a	48.03 ± 2.76a	36.22 ± 2.80b	32.11 ± 2.74b , c
RV/LV + S	0.25 ± 0.01	0.41 ± 0.02a	0.39 ± 0.01a	0.32 ± 0.01b	0.32 ± 0.01b , c
RV/LV EDA	0.31 ± 0.01	0.71 ± 0.04a	0.65 ± 0.05a	0.37 ± 0.01b	0.41 ± 0.02b , c
RV/LV EF	0.73 ± 0.01	0.56 ± 0.03a	0.53 ± 0.03a	0.69 ± 0.04b	0.67 ± 0.04b , c

ASCs or CM were injected through the jugular vein after 7 days of Bleo instillation. Following 2 weeks of Bleo instillation, ECHO and haemodynamic parameters were assessed. Data demonstrate the improvement in cardiac function and haemodynamics in the Bleo animals in presence of ASCs or CM. Data presented are mean ± SEM, Con (n = 8), B (n = 8), B + M (n = 6), BAD7 (n = 7), and BCM7 (n = 7).

^a P ≤ 0.05, comparing B and B + M animals against the controls.

^b P ≤ 0.05, comparing BAD7 and BCM7 versus B.

^c P ≤ 0.05, comparing BCM7 versus B + M.